UK Markets close in 1 hr 40 mins

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
599.20-9.04 (-1.49%)
As of 9:50AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close608.24
Open601.11
Bid598.60 x 1300
Ask599.60 x 1400
Day's range592.45 - 608.23
52-week range271.37 - 664.64
Volume70,037
Avg. volume1,233,564
Market cap63.75B
Beta (5Y monthly)0.55
PE ratio (TTM)23.20
EPS (TTM)25.83
Earnings date03 Nov 2020 - 09 Nov 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est673.84
  • Coronavirus update: Kodak federal loan in jeopardy; Gilead seeks approval of remdesivir
    Editor's pick
    Yahoo Finance

    Coronavirus update: Kodak federal loan in jeopardy; Gilead seeks approval of remdesivir

    Top stories about how the coronavirus pandemic is affecting business around the world.

  • Regeneron's (REGN) Q2 Earnings & Sales Surpass Estimates
    Zacks

    Regeneron's (REGN) Q2 Earnings & Sales Surpass Estimates

    Regeneron (REGN) beats on Q2 earnings and sales on solid performance of Dupixent and oncology drug, Libtayo.

  • Reuters

    Regeneron profit beats, expects early results from COVID-19 trials in September

    Regeneron is among several drugmakers racing to develop a treatment for the novel coronavirus and earlier this week said its experimental COVID-19 antibody drug combination, REGN-COV2, prevented and treated the disease in rhesus macaques and hamsters. Continued lockdowns to curb the spread of the coronavirus have prompted patients to reschedule their hospital visits, weighing on sales of physician-administered drugs such as Regeneron's blockbuster drug Eylea. U.S. sales of Eylea, approved for treating wet age-related macular degeneration, fell to $1.11 billion from $1.16 billion, but came in above Wall Street estimates of $1.06 billion, according to brokerage Piper Sandler.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more